Bie-Jia-Jian Pill: Inhibiting tumor glycolysis and promoting CD8+ cell-mediated anti-tumor immunity by targeting HIF-1α-PI3K/AKT/mTOR and CCL20 in hepatocellular carcinoma

肝细胞癌 糖酵解 免疫 癌症研究 医学 免疫系统 转移 20立方厘米 细胞免疫 癌 癌症 免疫学 先天免疫系统 生物 肿瘤细胞 肿瘤免疫学 厌氧糖酵解 药理学
作者
Yang Liu,Xuemei Yang,Mengchen Qin,Weicong Chen,Changshun Liu,Wentao Jiang,Yiqin Wang,Sirui Tan,Haiyan Sun,Jingfei Chen,Haitao Sun,Songqi He
出处
期刊:Journal of Ethnopharmacology [Elsevier BV]
卷期号:365: 121554-121554 被引量:4
标识
DOI:10.1016/j.jep.2026.121554
摘要

The efficacy of immunotherapy for hepatocellular carcinoma (HCC) is often limited by an immunosuppressive tumor microenvironment (TME), largely driven by tumor metabolic reprogramming (the Warburg effect) that impairs CD8+ T cells. Targeting this metabolism to restore immunity is a promising strategy. Bie-Jia-Jian Pill (BJJP), a traditional formula for “softening hardness and dissipating masses,” conceptually aligns with modulating the TME. However, its role in reprogramming tumor metabolism to enhance immunotherapy remains unclear. We aimed to investigate if BJJP enhances anti-tumor immunity by inhibiting the Warburg effect, elucidate its molecular mechanism, and evaluate its synergy with PD-L1 blockade. Using UHPLC-MS, the major components of BJJP were analyzed and its efficacy was evaluated in combination with the PD-L1 neutralizing antibody for HCC treatment. CD8+ T cells and tumor markers were assessed in vitro and in vivo using flow cytometry. Transcriptomics, metabolomics, Seahorse metabolic assays, Western blotting, ELISA, and immunofluorescence staining were employed to identify and validate the mechanisms and targets of BJJP. Its targeting capabilities were confirmed by lentivirus and siRNA transfections, network pharmacology and molecular docking. BJJP suppressed HCC cell proliferation, growth and migration, promoted their apoptosis, reduced PD-L1 expression, and enhanced CD8+ T cell cytotoxicity and infiltration in the tumor. BJJP and immunotherapy exerted synergistic effects, including inhibiting tumor cell proliferation, increasing immune cell infiltration, and improving treatment efficacy. BJJP suppressed glycolysis in HCC cells, alleviated the excessive uptake of energy substrates, and reduced lactate accumulation in the microenvironment, thereby mitigating CD8+ T cell exhaustion. This glycolytic metabolic reprogramming was related to BJJP’s effect on inhibiting the HIF-1α-PI3K/AKT/mTOR axis. Additionally, BJJP inhibited the downstream NF-κB activation, down-regulated CCL20, and alleviated the inhibitory effect of CCL20 against CD8+ T cells. BJJP targets the HIF-1α-PI3K/AKT/mTOR axis to reprogram tumor glycolysis, reduce CCL20 secretion, enhance CD8+ T cell immune response, and modulate the tumor microenvironment, thereby exerting anti-tumor effects against HCC. When used in combination with immunotherapy, BJJP can improve treatment efficacy, providing valuable evidence for clinical treatment. • Synergistic Therapy: This study demonstrates, for the first time, that the traditional Chinese medicine Bie-Jia-Jian Pill (BJJP) synergizes with anti-PD-L1 immunotherapy to significantly inhibit hepatocellular carcinoma (HCC) growth and improve treatment efficacy. • Metabolic-Immune Reprogramming: BJJP directly reprograms glycolytic metabolism in HCC cells by inhibiting the HIF-1α-PI3K/AKT/mTOR signaling axis, thereby reducing lactate production and alleviating CD8 + T cell exhaustion in the tumor microenvironment. • Enhanced CD8 + T Cell Function: Beyond metabolic modulation, BJJP diminishes the secretion of the chemokine CCL20 via NF-κB downregulation, which further mitigates its suppressive effect on CD8 + T cells, promoting their infiltration and cytotoxic function. • Multi-omics Validation: The mechanistic insights are robustly supported by a combination of transcriptomic, metabolomic, and functional analyses (Seahorse assay, flow cytometry, in vivo models), providing a comprehensive pharmacological basis for BJJP. • Clinical Translation : The findings position BJJP as a promising adjuvant agent to enhance the effectiveness of current immunotherapy in HCC, bridging traditional medicine and modern immuno-oncology.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
明朗完成签到 ,获得积分10
刚刚
Da_Li完成签到,获得积分10
1秒前
茹果完成签到,获得积分10
1秒前
稳重依萱完成签到 ,获得积分10
1秒前
啦啦啦啦完成签到,获得积分10
1秒前
Owen的应助被sendou采纳,获得10
2秒前
李子发布了新的文献求助10
3秒前
zrf完成签到,获得积分10
4秒前
4秒前
5秒前
bearcat完成签到,获得积分10
5秒前
twive完成签到,获得积分10
5秒前
5秒前
monalisuo完成签到,获得积分10
5秒前
coolru的应助被大白采纳,获得10
5秒前
CodeCraft的应助被pink采纳,获得10
5秒前
5秒前
怕孤独的傲丝完成签到,获得积分10
6秒前
6秒前
nnn发布了新的文献求助10
6秒前
小马甲的应助被辛勤的芷天采纳,获得10
6秒前
6秒前
rhx发布了新的文献求助10
6秒前
七月完成签到,获得积分10
7秒前
大模型的应助被XX采纳,获得10
8秒前
念安完成签到,获得积分20
8秒前
Maestro_S的应助被kk采纳,获得10
8秒前
xiett完成签到 ,获得积分10
9秒前
fantasy的应助被七月流火采纳,获得10
9秒前
10秒前
希望天下0贩的0的应助被张张采纳,获得10
10秒前
10秒前
罐装发布了新的文献求助10
10秒前
拥你入怀发布了新的文献求助10
10秒前
rick的应助被momoko采纳,获得10
10秒前
英姑的应助被小黑球采纳,获得10
11秒前
殷勤的紫槐的应助被李思超采纳,获得240
11秒前
园园完成签到,获得积分10
11秒前
11秒前
小面包发布了新的文献求助10
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8168144
求助须知:如何正确求助?哪些是违规求助? 9561199
关于积分的说明 21759542
捐赠科研通 7759434
什么是DOI,文献DOI怎么找? 3429948
关于科研通互助平台的介绍 2553742
邀请新用户注册赠送积分活动 2474463